RENOGENYX is a biotechnology company developing therapeutics for facioscapulohumeral muscular dystrophy (FSHD), which affects over 1 million people worldwide. We are developing epigenetic tools to treat the root cause of disease. Our mission? To change the lives of people living with FSHD through the development of safe and effective treatments. Our most advanced preclinical program is a CRISPR-based approach called CRISPR inhibition (CRISPRi) to treat the underlying cause of FSHD. We aim to bring it to the clinic and ultimately to patients, utilizing all-in-one therapeutic cassettes that enable the use of epigenetic modulators in AAV-mediated gene therapy.  RENOGENYX is a spinout from the University of Nevada, Reno School of Medicine that brings together an international consortium of leaders in FSHD research with experts in translational drug development and commercialization.  Our scientists have expertise in the fields of epigenetics, gene regulation, biochemistry, genetics, molecular biology, developmental biology, cell and muscle biology, muscle disease, novel drug discovery and disease diagnostics for rare genetic disorders.